These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 34809526)
1. Real-world safety of nusinersen in Japan: results from an interim analysis of a post-marketing surveillance and safety database. Wataya T; Takasaki S; Hoshino M; Makioka H; Nakamura G; Matsuda N Int J Neurosci; 2023 Dec; 133(8):851-863. PubMed ID: 34809526 [TBL] [Abstract][Full Text] [Related]
2. Real-world safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 401 Japanese patients: results from an interim analysis of post-marketing surveillance. Tachibana Y; Takasaki S; Hoshino M; Makioka H; Jin M Int J Neurosci; 2024 Jun; 134(2):153-162. PubMed ID: 35787224 [No Abstract] [Full Text] [Related]
3. A Post-Marketing Surveillance Study of Nusinersen for Spinal Muscular Atrophy in Routine Medical Practice in China: Interim Results. Jiang Y; Wang Y; Xiong H; Li W; Luo R; Chen W; Yin F; Lü J; Liang J; Chen WJ; Lu X; Wang H; Tang J; Monine M; Makepeace C; Jin X; Foster R; Chin R; Berger Z Adv Ther; 2024 Jul; 41(7):2743-2756. PubMed ID: 38722537 [TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 524 patients: results from an interim analysis of post-marketing surveillance in Japan. Tachibana Y; Sato R; Makioka H; Hoshino M; Jin M Int J Neurosci; 2023 Sep; ():1-13. PubMed ID: 37649429 [TBL] [Abstract][Full Text] [Related]
5. Nusinersen effectiveness and safety in pediatric patients with 5q-spinal muscular atrophy: a multi-center disease registry in China. Yao X; Peng J; Luo R; Wang X; Lu X; Wu L; Jin R; Zhong J; Liang J; Hong S; Yang L; Zhang X; Mao S; Hu J; Tao Z; Sun D; Wang H; Zhang L; Xia Y; Chen K; Wang Y J Neurol; 2024 Aug; 271(8):5378-5391. PubMed ID: 38954034 [TBL] [Abstract][Full Text] [Related]
6. Disproportionality Analysis of Nusinersen in the Food and Drug Administration Adverse Event Reporting System: A Real-World Postmarketing Pharmacovigilance Assessment. Li Y; Zhang N; Jiang T; Gan L; Su H; Wu Y; Yang X; Xiang G; Ni R; Xu J; Li C; Liu Y Pediatr Neurol; 2024 Sep; 158():71-78. PubMed ID: 38981277 [TBL] [Abstract][Full Text] [Related]
7. Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1-3 patients treated with nusinersen. Šimić G; Vukić V; Babić M; Banović M; Berečić I; Španić E; Zubčić K; Golubić AT; Barišić Kutija M; Merkler Šorgić A; Vogrinc Ž; Lehman I; Hof PR; Sertić J; Barišić N CNS Neurosci Ther; 2024 Mar; 30(3):e14051. PubMed ID: 36513962 [TBL] [Abstract][Full Text] [Related]
8. Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis. Gavriilaki M; Moschou M; Papaliagkas V; Notas K; Chatzikyriakou E; Papagiannopoulos S; Arnaoutoglou M; Kimiskidis VK Neurotherapeutics; 2022 Mar; 19(2):464-475. PubMed ID: 35178673 [TBL] [Abstract][Full Text] [Related]
9. Unilateral interlaminar fenestration on the convex side provides a reliable access for intrathecal administration of nusinersen in spinal muscular atrophy: a retrospective study. Wang Z; Feng E; Jiao Y; Zhao J; Chen X; Zhang H; Liang J; Li Z; Cui X; Chen W; Shen J Orphanet J Rare Dis; 2023 Nov; 18(1):369. PubMed ID: 38031122 [TBL] [Abstract][Full Text] [Related]
10. Correlations between clinical motor scores and CMAP in patients with type 2 spinal muscular amyotrophy treated with nusinersen. Richard M; Barrois R; Desguerre I; Deladrière E; Leloup-Germa V; Barnerias C; Gitiaux C Arch Pediatr; 2024 Jan; 31(1):26-31. PubMed ID: 37989659 [TBL] [Abstract][Full Text] [Related]
11. Improvements in Walking Distance during Nusinersen Treatment - A Prospective 3-year SMArtCARE Registry Study. Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Steinbach M; Blaschek A; Baumann M; Baumgartner M; Becker B; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Küpper H; Johannsen J; Kamm C; Koch JC; Köhler C; Kölbel H; Kolzter K; von Moers A; Naegel S; Neuwirth C; Petri S; Rödiger A; Schimmel M; Schrank B; Schreiber G; Smitka M; Stadler C; Steiner E; Stögmann E; Trollmann R; Türk M; Weiler M; Stoltenburg C; Willichowsky E; Zeller D; Ziegler A; Lochmüller H; Kirschner J; J Neuromuscul Dis; 2023; 10(1):29-40. PubMed ID: 36565133 [TBL] [Abstract][Full Text] [Related]
12. Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study. Zhuang W; Lu M; Wu Y; Chen Z; Wang M; Wang X; Guan S; Lin W Clin Drug Investig; 2023 Dec; 43(12):949-962. PubMed ID: 37995087 [TBL] [Abstract][Full Text] [Related]
13. Switching from Nusinersen to Risdiplam: A Croatian Real-World Experience on Effectiveness and Safety. Belančić A; Strbad T; Kučan Štiglić M; Vitezić D J Pers Med; 2024 Feb; 14(3):. PubMed ID: 38540986 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Nusinersen in Type 1, 2 and 3 Spinal Muscular Atrophy: Croatian Real-World Data. Belančić A; Strbad T; Kučan Štiglić M; Vitezić D J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109175 [TBL] [Abstract][Full Text] [Related]
15. Adverse events in the treatment of spinal muscular atrophy in children and adolescents with nusinersen: A systematic review and meta-analysis. Zhong ZJ; Zheng PM; Dou HH; Wang JG Front Pediatr; 2023; 11():1152318. PubMed ID: 37181426 [TBL] [Abstract][Full Text] [Related]
16. DEVOTE Study Exploring Higher Dose of Nusinersen in Spinal Muscular Atrophy: Study Design and Part A Results. Finkel RS; Day JW; Pascual Pascual SI; Ryan MM; Mercuri E; De Vivo DC; Montes J; Gurgel-Giannetti J; Monine M; Gambino G; Makepeace C; Foster R; Berger Z; J Neuromuscul Dis; 2023; 10(5):813-823. PubMed ID: 37393513 [TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post-marketing surveillance. Uhara H; Kiyohara Y; Isei T; Nagase K; Kambe A; Sato M; Tanaka Y; Yamazaki N J Dermatol; 2024 Apr; 51(4):475-483. PubMed ID: 38433375 [TBL] [Abstract][Full Text] [Related]
18. Safety of risdiplam in spinal muscular atrophy patients after short-term treatment with nusinersen. Yan Y; Feng Y; Jiang L; Jin J; Mao S Muscle Nerve; 2024 Aug; ():. PubMed ID: 39136364 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological Therapies of Spinal Muscular Atrophy: A Narrative Review of Preclinical, Clinical-Experimental, and Real-World Evidence. Crisafulli S; Boccanegra B; Vitturi G; Trifirò G; De Luca A Brain Sci; 2023 Oct; 13(10):. PubMed ID: 37891814 [TBL] [Abstract][Full Text] [Related]
20. Study on the efficacy, safety, and biomarkers of nusinersen in type II and III spinal muscular atrophy in children. Chen L; Liu F; Fang D; Li J Front Pediatr; 2023; 11():1294405. PubMed ID: 38111627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]